Longitudinal hematologic decline during peginterferon alfa-2b therapy in chronic hepatitis B: clinical safety and exploratory whole-blood transcriptomics.

Li J, Chen W, Chen J, Xing J, Chen Q, Zhang J, Shi R, Pan C, Chen Y

DOI: 10.3389/fmed.2026.1919392
Published: 2026
Container: Frontiers in medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fmed.2026.1919392,
  title = {Longitudinal hematologic decline during peginterferon alfa-2b therapy in chronic hepatitis B: clinical safety and exploratory whole-blood transcriptomics.},
  author = {Li J and Chen W and Chen J and Xing J and Chen Q and Zhang J and Shi R and Pan C and Chen Y},
  year = {2026},
  journal = {Frontiers in medicine},
  doi = {10.3389/fmed.2026.1919392},
  url = {https://doi.org/10.3389/fmed.2026.1919392}
}

RIS

TY  - JOUR
TI  - Longitudinal hematologic decline during peginterferon alfa-2b therapy in chronic hepatitis B: clinical safety and exploratory whole-blood transcriptomics.
AU  - Li J
AU  - Chen W
AU  - Chen J
AU  - Xing J
AU  - Chen Q
AU  - Zhang J
AU  - Shi R
AU  - Pan C
AU  - Chen Y
PY  - 2026
JO  - Frontiers in medicine
DO  - 10.3389/fmed.2026.1919392
UR  - https://doi.org/10.3389/fmed.2026.1919392
ER  -

APA

J, L., W, C., J, C., J, X., Q, C., J, Z., R, S., C, P., & Y, C. (2026). Longitudinal hematologic decline during peginterferon alfa-2b therapy in chronic hepatitis B: clinical safety and exploratory whole-blood transcriptomics.. Frontiers in medicine. https://doi.org/10.3389/fmed.2026.1919392

Source records

pubmed · retrieved 2026-11-10T19:14:02.510Z